DE1003496T1 - Methode zur Vorbeugung von Prostatakrebs - Google Patents

Methode zur Vorbeugung von Prostatakrebs

Info

Publication number
DE1003496T1
DE1003496T1 DE1003496T DE99924157T DE1003496T1 DE 1003496 T1 DE1003496 T1 DE 1003496T1 DE 1003496 T DE1003496 T DE 1003496T DE 99924157 T DE99924157 T DE 99924157T DE 1003496 T1 DE1003496 T1 DE 1003496T1
Authority
DE
Germany
Prior art keywords
prostate cancer
preventing prostate
intraepithelial neoplasia
prostate
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1003496T
Other languages
English (en)
Inventor
Mitchell S Steiner
Sharon Raghow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of DE1003496T1 publication Critical patent/DE1003496T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE1003496T 1998-05-07 1999-05-07 Methode zur Vorbeugung von Prostatakrebs Pending DE1003496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8460298P 1998-05-07 1998-05-07
PCT/US1999/010146 WO1999056739A1 (en) 1998-05-07 1999-05-07 A method for chemoprevention of prostate cancer

Publications (1)

Publication Number Publication Date
DE1003496T1 true DE1003496T1 (de) 2000-11-02

Family

ID=22186034

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1003496T Pending DE1003496T1 (de) 1998-05-07 1999-05-07 Methode zur Vorbeugung von Prostatakrebs
DE69922131T Expired - Lifetime DE69922131T2 (de) 1998-05-07 1999-05-07 Medikament zur behandlung intraepithelialer prostataneoplasie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69922131T Expired - Lifetime DE69922131T2 (de) 1998-05-07 1999-05-07 Medikament zur behandlung intraepithelialer prostataneoplasie

Country Status (26)

Country Link
US (1) US6265448B1 (de)
EP (3) EP2277514A1 (de)
JP (2) JP4482229B2 (de)
AT (1) ATE283043T1 (de)
AU (1) AU761435B2 (de)
BG (1) BG65597B1 (de)
CA (1) CA2323809C (de)
CZ (1) CZ300960B6 (de)
DE (2) DE1003496T1 (de)
DK (1) DK1003496T3 (de)
EA (1) EA003466B1 (de)
ES (1) ES2145730T3 (de)
HR (1) HRP20000729A2 (de)
HU (1) HUP0102068A3 (de)
IL (3) IL138437A0 (de)
IS (2) IS2213B (de)
NO (1) NO20005625L (de)
NZ (1) NZ527522A (de)
PL (1) PL207462B1 (de)
PT (1) PT1003496E (de)
SI (1) SI1003496T1 (de)
SK (1) SK16642000A3 (de)
TR (1) TR200003269T2 (de)
UA (1) UA74532C2 (de)
WO (1) WO1999056739A1 (de)
YU (1) YU68600A (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413535B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
CZ300960B6 (cs) * 1998-05-07 2009-09-23 The University Of Tennessee Research Corporation Lécivo pro lécení prostatické intraepitelové neoplasie
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
WO2001017479A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
PT1666033E (pt) 2001-11-29 2009-02-09 Gtx Inc Prevenção e tratamento de osteoporose induzida pela falta de androgénio
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US20050208159A1 (en) * 2004-03-16 2005-09-22 Kang Kyung S Phytoestrogenic composition comprising an extract of chinese licorice root, liquiritin or isoliquiritin
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
USD969722S1 (en) 2021-09-28 2022-11-15 Wagner Delima Stabilizing wedge pad

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
ATE198271T1 (de) * 1992-12-01 2001-01-15 Biotie Therapies Oy Syndecan-stimulierung der zellulären differenzierung
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
JPH09501174A (ja) 1993-08-09 1997-02-04 バラル、エドワード キラー細胞媒介細胞融解に対するガン細胞の増感方法
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
ZA984650B (en) * 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
CZ300960B6 (cs) * 1998-05-07 2009-09-23 The University Of Tennessee Research Corporation Lécivo pro lécení prostatické intraepitelové neoplasie

Also Published As

Publication number Publication date
AU761435B2 (en) 2003-06-05
DK1003496T3 (da) 2005-04-04
DE69922131D1 (de) 2004-12-30
US6265448B1 (en) 2001-07-24
IS5700A (is) 2000-11-01
DE69922131T2 (de) 2005-11-24
IL193231A0 (en) 2009-02-11
WO1999056739A1 (en) 1999-11-11
JP2002513755A (ja) 2002-05-14
NZ527522A (en) 2005-04-29
EP1475087A3 (de) 2007-07-11
JP4482229B2 (ja) 2010-06-16
PT1003496E (pt) 2005-04-29
BG65597B1 (bg) 2009-02-27
AU4072699A (en) 1999-11-23
PL344000A1 (en) 2001-09-10
IL138437A0 (en) 2001-10-31
CA2323809C (en) 2007-09-18
BG105022A (bg) 2001-07-31
EP1003496A1 (de) 2000-05-31
CZ300960B6 (cs) 2009-09-23
PL207462B1 (pl) 2010-12-31
HUP0102068A2 (hu) 2002-05-29
IS8354A (is) 2006-03-15
UA74532C2 (en) 2006-01-16
ES2145730T1 (es) 2000-07-16
HUP0102068A3 (en) 2002-11-28
EP1003496B1 (de) 2004-11-24
EP1475087A2 (de) 2004-11-10
SI1003496T1 (en) 2005-10-31
ES2145730T3 (es) 2005-06-16
EA003466B1 (ru) 2003-06-26
IS2213B (is) 2007-03-15
CZ20004118A3 (cs) 2002-07-17
ATE283043T1 (de) 2004-12-15
EA200000100A1 (ru) 2000-08-28
CA2323809A1 (en) 1999-11-11
SK16642000A3 (sk) 2002-08-06
HRP20000729A2 (en) 2001-06-30
JP2008163048A (ja) 2008-07-17
YU68600A (sh) 2003-12-31
IL138437A (en) 2008-12-29
NO20005625L (no) 2001-01-05
NO20005625D0 (no) 2000-11-07
EP2277514A1 (de) 2011-01-26
TR200003269T2 (tr) 2001-02-21

Similar Documents

Publication Publication Date Title
DE1003496T1 (de) Methode zur Vorbeugung von Prostatakrebs
BR9806118A (pt) Processos para tratamento de pigmentação de pele
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
WO2001076514A3 (en) Methods and devices for treating fractured and/or diseased bone
WO2000037107A3 (en) Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
EA200400744A1 (ru) Предупреждение и лечение остеопороза, вызванного депривацией андрогенов
DE60142084D1 (de) Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten
BR0312040A (pt) Oxidação de compostos orgânicos
WO1999043355A3 (en) Formulations containing oxaliplatin
WO2002076380A3 (en) Cytotoxic factors for modulating cell death
WO2003000707A3 (en) Antisense modulation of superoxide dismutase 1, soluble expression
BR0003184A (pt) Métodos para tratamento de pigmentação da pele
WO2002076499A3 (en) Combination treatment of pancreatic cancer
ATE363267T1 (de) Mittel zur verbesserung der hauttextur
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU4779599A (en) Methods of inhibiting (helicobacter pylori)
WO2003053365A3 (en) Syn3 compositions and methods
AP2003002740A0 (en) Vehicle used to apply chemical Compounds to wood.
BR9901381A (pt) Composições para a cura de polìmero
NO942074A (no) Fremgangsmåte for å fjerne uönsket farge fra saltsyre
EP0950411B8 (de) Verfahren zur Herstellung eines Extraktes aus Copalchirinde und Verwendung der Neoflavonoide zur Behandlung von Diabetes
ATE275192T1 (de) Neue therapeutische verwendungen der heterologen superoxiddismutasen (hsd), sowie verfahren zur selektierung dieser hsd
GR1003205B (el) Φαρμακοθεραπευτικες χρησεις δυο τετραυδροφουρανικων παραγωγων: τετραυδρο-ν,ν-διμεθυλ-5,5-διφαινυλ-3-φουρανομεθαναμινη (αε14) και τετραυδρο-ν,ν-διμεθυλ-2,2-διφαινυλ-3-φουρανομεθαναμινη (αε37)
UA32303A (uk) Спосіб лікування папіломатозу
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита